의료 분야 인지 기능 평가 및 교육 시장 규모, 점유율, 성장, 산업 분석 : 유형별, 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of cognitive assessment and training in healthcare Market

The global cognitive assessment and training in healthcare market size was valued at USD 5.91 billion in 2025. The market is projected to grow from USD 6.85 billion in 2026 to USD 26.32 billion by 2034, registering a robust CAGR of 19.50% during the forecast period (2026-2034). North America dominated the market with a 56.40% share in 2025, driven by strong technological adoption and regulatory approvals for digital cognitive tools.

Cognitive assessment and training tools are designed to evaluate mental functioning and help diagnose neurological disorders such as Alzheimer's disease, dementia, mild cognitive impairment (MCI), depression, and other cognitive conditions. These tools assist healthcare professionals in detecting early cognitive decline and monitoring patient progress during treatment and clinical trials.

Market Drivers

Rising Prevalence of Neurological Disorders

The growing burden of neurological disorders is a primary growth driver. The prevalence of MCI globally stands at approximately 15-20%, while dementia affects millions worldwide. In the U.S. alone, around 6.7 million individuals aged 65 and above were living with Alzheimer's disease. Increasing awareness of early diagnosis and cognitive screening has accelerated demand for digital and traditional assessment tools.

Growth in Clinical Trials for Neurological Diseases

The expansion of clinical trials for Alzheimer's and other neurological conditions significantly fuels market growth. As of recent global data, over 160 clinical trials assessing more than 120 drug candidates for Alzheimer's disease are underway. Cognitive assessment tools are critical in monitoring treatment effectiveness and cognitive changes in enrolled patients. The growing requirement for remote and real-time cognitive monitoring strengthens the adoption of digital platforms.

Market Trends

Rising Adoption of Decentralized and Virtual Clinical Trials

The COVID-19 pandemic accelerated the shift toward decentralized clinical trials (DCTs). Virtual trials utilize remote patient monitoring, wearable devices, and online cognitive assessments. These models improve patient participation and data collection efficiency.

Digital cognitive tools allow patients to complete assessments remotely, enabling researchers to monitor outcomes without in-person visits. This convenience has significantly boosted the integration of digital cognitive solutions in healthcare, especially in large-scale neurological studies.

Restraining Factors

Despite rapid growth, certain challenges limit market expansion. The high cost of cognitive assessment packages-ranging between USD 600 and USD 1,200 in some regions-restricts accessibility. Additionally, concerns about accuracy and cut-off scoring in standardized tests such as MoCA may result in misdiagnosis. These limitations may slow adoption, particularly in developing economies.

Market Segmentation Analysis

By Assessment Type

The market is segmented into pen and paper, biometrics, and hosted solutions.

The pen and paper segment dominated in 2026 with a 46.58% share, primarily due to cost-effectiveness and integration with AI-powered analysis tools. Emerging AI-enhanced drawing-based tests are improving diagnostic accuracy.

The biometrics segment is expected to grow at the fastest CAGR due to increasing use of digital biomarkers and advanced neurological monitoring technologies.

By Application

Based on application, the market includes screening & diagnostics, clinical trials, brain training, and others.

The clinical trials segment led the market with a 43.22% share in 2026, driven by increasing product launches aimed at improving cognitive assessment efficiency. Growing Alzheimer's drug development pipelines continue to support this segment.

The screening and diagnostics segment is projected to witness the fastest growth due to increased awareness and partnerships offering digital cognitive screening solutions.

Regional Insights

North America

North America accounted for USD 3.33 billion in 2025 and grew to USD 3.92 billion in 2026. The U.S. market reached USD 3.71 billion in 2026. Growth is supported by FDA approvals of digital cognitive tools, increasing R&D investments, and high prevalence of neurological diseases.

Europe

Europe is expected to record the fastest growth rate during the forecast period. The UK market reached USD 0.48 billion in 2026, while Germany accounted for USD 0.61 billion in 2026. Strong presence of leading companies and increasing demand for early diagnosis drive regional growth.

Asia Pacific

Asia Pacific is projected to grow substantially. Japan's market reached USD 0.15 billion in 2026, China accounted for USD 0.19 billion in 2026, and India reached USD 0.07 billion in 2026. Expanding strategic partnerships and rising awareness are key growth contributors.

The Rest of the World, including Latin America and the Middle East & Africa, is expected to show steady growth due to improving healthcare infrastructure and awareness initiatives.

Competitive Landscape

Prominent players include Cambridge Cognition Ltd, Pearson, Cogstate Ltd, PAR, Inc., CogniFit Inc., Clario, Signant Health, and Koninklijke Philips N.V. Companies are strengthening market positions through acquisitions, partnerships, and AI-based product launches. Strategic collaborations and digital innovation remain central to competitive advantage.

Conclusion

The cognitive assessment and training in healthcare market is poised for remarkable expansion, growing from USD 5.91 billion in 2025 to USD 26.32 billion by 2034, at a CAGR of 19.50%. Increasing neurological disease prevalence, rising clinical trial activity, and rapid digital transformation in healthcare are major growth drivers. While high costs and assessment limitations pose challenges, technological advancements and decentralized trial adoption are expected to offset these barriers. North America remains the dominant region, while Europe and Asia Pacific offer significant growth opportunities. Continuous innovation and global expansion strategies will be crucial for sustained market leadership through 2034.

Segmentation By Assessment Type

• Pen and Paper
• Biometrics
• Hosted

By Application

• Screening and Diagnostics
• Clinical Trials
• Brain Training
• Others

By Region

• North America (By Assessment Type, Application, and Country)
  • U.S.
  • Canada
• Europe (By Assessment Type, Application, and Country/Sub-region)
  • U.K.
  • Germany
  • France
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Assessment Type, Application, and Country/Sub-region)
  • China
  • India
  • Japan
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Rest of the World (By Assessment Type, Application)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Number of Clinical Trials Conducted - by Key Countries, 2025
• 4.2. Prevalence of Mild Cognitive Impairment (MCI) - by Key Countries, 2025
• 4.3. Key Industry Developments (Mergers, Acquisitions, Partnerships; etc.)
• 4.4. Impact of COVID-19 on the Market

5. Global Cognitive Assessment and Training in Healthcare Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Assessment Type
  • 5.1.1. Pen and Paper
  • 5.1.2. Biometrics
  • 5.1.3. Hosted
• 5.2. Market Analysis, Insights and Forecast - By Application
  • 5.2.1. Screening and Diagnostics
  • 5.2.2. Clinical Trials
  • 5.2.3. Brain Training
  • 5.2.4. Others
• 5.3. Market Analysis, Insights and Forecast - By Region
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. Asia Pacific
  • 5.3.4. Rest of the World

6. North America Cognitive Assessment and Training in Healthcare Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Assessment Type
  • 6.1.1. Pen and Paper
  • 6.1.2. Biometrics
  • 6.1.3. Hosted
• 6.2. Market Analysis, Insights and Forecast - By Application
  • 6.2.1. Screening and Diagnostics
  • 6.2.2. Clinical Trials
  • 6.2.3. Brain Training
  • 6.2.4. Others
• 6.3. Market Analysis, Insights and Forecast - By Country
  • 6.3.1. U.S.
  • 6.3.2. Canada

7. Europe Cognitive Assessment and Training in Healthcare Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Assessment Type
  • 7.1.1. Pen and Paper
  • 7.1.2. Biometrics
  • 7.1.3. Hosted
• 7.2. Market Analysis, Insights and Forecast - By Application
  • 7.2.1. Screening and Diagnostics
  • 7.2.2. Clinical Trials
  • 7.2.3. Brain Training
  • 7.2.4. Others
• 7.3. Market Analysis, Insights and Forecast - By Country/Sub-Region
  • 7.3.1. Germany
  • 7.3.2. U.K.
  • 7.3.3. France
  • 7.3.4. Italy
  • 7.3.5. Spain
  • 7.3.6. Scandinavia
  • 7.3.7. Rest of Europe

8. Asia Pacific Cognitive Assessment and Training in Healthcare Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Assessment Type
  • 8.1.1. Pen and Paper
  • 8.1.2. Biometrics
  • 8.1.3. Hosted
• 8.2. Market Analysis, Insights and Forecast - By Application
  • 8.2.1. Screening and Diagnostics
  • 8.2.2. Clinical Trials
  • 8.2.3. Brain Training
  • 8.2.4. Others
• 8.3. Market Analysis, Insights and Forecast - By Country/Sub-Region
  • 8.3.1. China
  • 8.3.2. Japan
  • 8.3.3. India
  • 8.3.4. Australia
  • 8.3.5. Southeast Asia
  • 8.3.6. Rest of Asia Pacific

9. Rest of the World Cognitive Assessment and Training in Healthcare Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Assessment Type
  • 9.1.1. Pen and Paper
  • 9.1.2. Biometrics
  • 9.1.3. Hosted
• 9.2. Market Analysis, Insights and Forecast - By Application
  • 9.2.1. Screening and Diagnostics
  • 9.2.2. Clinical Trials
  • 9.2.3. Brain Training
  • 9.2.4. Others

10. Competitive Analysis

• 10.1. Global Market Share Analysis (2025)
• 10.2. Company Profiles
  • 10.2.1. Cambridge Cognition Ltd
    • 10.2.1.1. Overview
    • 10.2.1.2. Products
    • 10.2.1.3. SWOT Analysis
    • 10.2.1.4. Recent Developments
    • 10.2.1.5. Strategies
    • 10.2.1.6. Financials (Based on Availability)
  • 10.2.2. CogniFit Inc
    • 10.2.2.1. Overview
    • 10.2.2.2. Products
    • 10.2.2.3. SWOT Analysis
    • 10.2.2.4. Recent Developments
    • 10.2.2.5. Strategies
    • 10.2.2.6. Financials (Based on Availability)
  • 10.2.3. Cogstate Ltd.
    • 10.2.3.1. Overview
    • 10.2.3.2. Products
    • 10.2.3.3. SWOT Analysis
    • 10.2.3.4. Recent Developments
    • 10.2.3.5. Strategies
    • 10.2.3.6. Financials (Based on Availability)
  • 10.2.4. CNS Vital Signs, LLC.
    • 10.2.4.1. Overview
    • 10.2.4.2. Products
    • 10.2.4.3. SWOT Analysis
    • 10.2.4.4. Recent Developments
    • 10.2.4.5. Strategies
    • 10.2.4.6. Financials (Based on Availability)
  • 10.2.5. WIRB-Copernicus Group
    • 10.2.5.1. Overview
    • 10.2.5.2. Products
    • 10.2.5.3. SWOT Analysis
    • 10.2.5.4. Recent Developments
    • 10.2.5.5. Strategies
    • 10.2.5.6. Financials (Based on Availability)
  • 10.2.6. Signant Health
    • 10.2.6.1. Overview
    • 10.2.6.2. Products
    • 10.2.6.3. SWOT Analysis
    • 10.2.6.4. Recent Developments
    • 10.2.6.5. Strategies
    • 10.2.6.6. Financials (Based on Availability)
  • 10.2.7. Posit Science
    • 10.2.7.1. Overview
    • 10.2.7.2. Products
    • 10.2.7.3. SWOT Analysis
    • 10.2.7.4. Recent Developments
    • 10.2.7.5. Strategies
    • 10.2.7.6. Financials (Based on Availability)
  • 10.2.8. Clario
    • 10.2.8.1. Overview
    • 10.2.8.2. Products
    • 10.2.8.3. SWOT Analysis
    • 10.2.8.4. Recent Developments
    • 10.2.8.5. Strategies
    • 10.2.8.6. Financials (Based on Availability)
  • 10.2.9. Cognetivity Neurosciences
    • 10.2.9.1. Overview
    • 10.2.9.2. Products
    • 10.2.9.3. SWOT Analysis
    • 10.2.9.4. Recent Developments
    • 10.2.9.5. Strategies
    • 10.2.9.6. Financials (Based on Availability)
  • 10.2.10. Linus Health
    • 10.2.10.1. Overview
    • 10.2.10.2. Products
    • 10.2.10.3. SWOT Analysis
    • 10.2.10.4. Recent Developments
    • 10.2.10.5. Strategies
    • 10.2.10.6. Financials (Based on Availability)
  • 10.2.11. Par Inc.
    • 10.2.11.1. Overview
    • 10.2.11.2. Products
    • 10.2.11.3. SWOT Analysis
    • 10.2.11.4. Recent Developments
    • 10.2.11.5. Strategies
    • 10.2.11.6. Financials (Based on Availability)
  • 10.2.12. KERNEL
    • 10.2.12.1. Overview
    • 10.2.12.2. Products
    • 10.2.12.3. SWOT Analysis
    • 10.2.12.4. Recent Developments
    • 10.2.12.5. Strategies
    • 10.2.12.6. Financials (Based on Availability)
  • 10.2.13. Neurotrack Technologies, Inc.
    • 10.2.13.1. Overview
    • 10.2.13.2. Products
    • 10.2.13.3. SWOT Analysis
    • 10.2.13.4. Recent Developments
    • 10.2.13.5. Strategies
    • 10.2.13.6. Financials (Based on Availability)
  • 10.2.14. Pearson
    • 10.2.14.1. Overview
    • 10.2.14.2. Products
    • 10.2.14.3. SWOT Analysis
    • 10.2.14.4. Recent Developments
    • 10.2.14.5. Strategies
    • 10.2.14.6. Financials (Based on Availability)
  • 10.2.15. Koninklijke Philips N.V.
    • 10.2.15.1. Overview
    • 10.2.15.2. Products
    • 10.2.15.3. SWOT Analysis
    • 10.2.15.4. Recent Developments
    • 10.2.15.5. Strategies
    • 10.2.15.6. Financials (Based on Availability)
  • 10.2.16. Winterlight Labs
    • 10.2.16.1. Overview
    • 10.2.16.2. Products
    • 10.2.16.3. SWOT Analysis
    • 10.2.16.4. Recent Developments
    • 10.2.16.5. Strategies
    • 10.2.16.6. Financials (Based on Availability)
  • 10.2.17. Aural Analytics
    • 10.2.17.1. Overview
    • 10.2.17.2. Products
    • 10.2.17.3. SWOT Analysis
    • 10.2.17.4. Recent Developments
    • 10.2.17.5. Strategies
    • 10.2.17.6. Financials (Based on Availability)